Disability in Multiple Sclerosis
Neurol 80:1018-1024, Kister, I.,et al, 2013
Association Between Immediate Initiation of Intramuscular Interferon Beta-1a at the Time of a Clinically Isolated Syndrome and Long-term Outcomes
Arch Neurol 69:183-190, Kinkel,R.P.,et al, 2012
Rapid Disease Course in African Americans With Multiple Sclerosis
Neurol 75:217-223, Kister,I., et al, 2010
MRI T2 Lesion Burden in Multiple Sclerosis. A Plateauing Relationship with Clinical Disability.
Neurol 66:1384-1389, Li,D.K.B.,et al, 2006
Infratentorial Lesions Predict Long-term Disability in Patients with Initial Findings Suggestive of Multiple Sclerosis
Arch Neurol 61:217-221, Minneboo,A.,et al, 2004
Clinical Implications of Benign Multiple Sclerosis: A 20-Year Population-Based Follow-Up Study
Ann Neurol 56:303-306, Pittock,S.J.,et al, 2004
A Longitudinal Study of Abnormalities on MRI and Disability From Multiple Sclerosis
NEJM 346:158-164,199, Brex,P.A.,et al, 2002
Early Onset Multiple Sclerosis
Neurol 59:1006-1010, Boiko,A.,et al, 2002
Relapses and Progression of Disability in Multiple Sclerosis
NEJM 343:1430-1438,1486, Confavreux,C.,et al, 2000
Benign Multiple Sclerosis? Clinical Course, Long Term Follow Up, and Assessment of Prognostic Factors
JNNP 67:148-152,138, Hawkins,S.A.&McDonnell,G.V., 1999
Doctors & Pts Don't Agree:Cross Sectional Study of Pts' & Doctors'Perceptions & Assessments of Disability in MS
BMJ 314:1580-1583, Rothwell,P.M.,et al, 1997
Life Expectancy in Patients Attending Multiple Sclerosis Clinics
Neurol 42:991-994, Sadovnick,A.D.,et al, 1992
Quality of Life in Multiple Sclerosis, Comparison with Inflam Bowel Dis & Rheumatic Arthritis
Arch Neurol 49:1237-1242, Rudick,R.A.,et al, 1992
Diet Quality is Associated with Disability and Symptom Severity in Multiple Sclerosis
Neurol 90:e1-e11, Fitzgerald, K.C.,et al, 2018
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
NEJM 365:1293-1303, OConnor, P.,et al, 2011
Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis
Arch Neurol 65:1044-1051, Krishnan,C.,et al., 2008
Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008
What Do We Really See When We Look at Magnetic Resonance Images?
Ann Neurol 62:207-208, Filippi,M. &Hartung,H.-P., 2007
Comparisons of Patient Self-report, Neurologic Examination, and Functional Impairment in MS
Neurol 56:934-937, Hoogervorst,E.L.J.,et al, 2001
Relative Contributions of Brain and Cervical Cord Pathology to Multiple Sclerosis Disability: a Study with Magnetisation Transfer Ratio Histogram Analysis
JNNP 69:723-727, Rovaris,M.,et al, 2000
Relevance of Hypointense Lesions on Fast Fluid-Attenuated Inversion Recovery MR Images as a Marker of Disease Severity in Cases of Multiple Sclerosis
AJNR 20:813-820, Rovaris,M.,et al, 1999
The Impact of Inpatient Rehabilitation on Progressive Multiple Sclerosis
Ann Neurol 42:236-244, Freeman,J.A.,et al, 1997
New Treatments for Multiple Sclerosis
BMJ 310:345-346, McDonald,W.I., 1995
Longitudinal MRI in Multiple Sclerosis:Correlation Between Disability and Lesion Burden
Neurol 44:2120-2124, Khoury,S.J.,et al, 1994
Interferon Beta-1b is Effective in Relapsing-Remitting MS
Clinical Results of a Placebo-Controlled Trial, IFNB MS Study Grp, Neurol 43:655-661, 64193., , 1993
Interferon Beta-1b is Effective in Relapsing Remitting MS, MRI Analysis Results of Placebo-Control Trial
Neurol 43:662-667, 6411993., Paty,D.W.,et al, 1993
Clinical Worsening in MS is Associated with Incr'd Freq & Area of Gadopenetate Dimeglumine-enhancing MRI Lesions
Ann Neurol 33:480-489, Smith,M.E.,et al, 1993
Event-Related Potential P300 in MS, Relation to Magnetic Resonance Imaging and Cognitive Impairment
Arch Neurol 49:44-50, Honig,L.S.,et al, 1992
A Correlative Triad of Gadolinium-DTPA MRI, EDSS, & CSF-MBP in Relapsing MS Treated with High-Dose Intravenous Methylprednisolone
Neurol 42:63-67, Barkhof,F.,et al, 1992
The Disability Status Scale for Multiple Sclerosis:Apologia Pro DSS Sau
Neurol 39:291-302, Kurtzke,J.F., 1989
Cognitive Loss in Multiple Sclerosis
Arch Neurol 46:162-167, Franklin,G.M.,et al, 1989
The Influence of Pregnancy on Disability From Multiple Sclerosis:A Population in Middlesex County, Ontario
Neurol 39:1438-1440, Weinshenker,B.G.,et al, 1989
Interrater Reliability in Assessing Functional Systems and Disability on the Kurtzke Scale in Multiple Sclerosis
Arch Neurol 45:746-748, Amato,M.P.,et al, 1988
Scales for Rating Impairment in Multiple Sclerosis:A Critique
Neurol 38:1793-1798, Willoughby,E.W.&Paty,D.W., 1988
Magnetic Resonance Imaging, Clinical Correlation in 64 Patients with Multiple Sclerosis
Arch Neurol 43:1145-1148, Stevens,J.C.,et al, 1986
A Neurologic Rating Scale (NRS) for Use in Multiple Sclerosis
Neurol 34:1368-1372, Sipe,J.C.,et al, 1984
An Illness Severity Score for Multiple Sclerosis
Neurol 34:1343-1347, Mickey,M.R.,et al, 1984
Rating Neurologic Impairment in Multiple Sclerosis:An Expanded Disability Status Scale (EDSS)
Neurol 33:1444-1452, Kurtzke,J.F., 1983
Multiple Sclerosis:Early Prognostic Guidelines
Arch Phys Med Rehab 62:54-58, Kraft,G.H.,et al, 1981